Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab

BACKGROUND: Blood-based biomarker such as circulating tumor DNA (ctDNA) has emerged as a promising tool for assessment of response to immunotherapy in solid tumors; But in hematological malignances, evidences are still lacking to support its clinical utility. In current study the feasibility of ctDN...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yuankai, Su, Hang, Song, Yongping, Jiang, Wenqi, Sun, Xiuhua, Qian, Wenbin, Zhang, Wei, Gao, Yuhuan, Jin, Zhengming, Zhou, Jianfeng, Jin, Chuan, Zou, Liqun, Qiu, Lugui, Li, Wei, Yang, Jianmin, Hou, Ming, Xiong, Yan, Zhou, Hui, Du, Xinhua, Wang, Xiong, Peng, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186760/
https://www.ncbi.nlm.nih.gov/pubmed/32304999
http://dx.doi.org/10.1016/j.ebiom.2020.102731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186760/
https://www.ncbi.nlm.nih.gov/pubmed/32304999
http://dx.doi.org/10.1016/j.ebiom.2020.102731

Ejemplares similares